Lisa Capparelli
Vice President of Investor Relations
Replay available
Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call
Arbutus Biopharma Corporation (NASDAQ: ABUS) Q2 2024 earnings conference call, held 2024-08-01. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mike McElhall
Interim President and Chief Executive Officer
Dr. Karen Sims
Chief Medical Officer
Dave Hastings
Chief Financial Officer
Dennis Ding
Analyst, Jefferies
Roy Buchanan
Analyst, Citizens
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arbutus Biopharma Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.175 Good day, and thank you for standing by. Welcome 00:00:03.175 -- 00:00:08.243 to the Arbitus Biopharma 2024 Second Quarter Financial Results and Corporate 00:00:08.243 -- 00:00:13.230 Update. At this time, all participants are in a listen-only mode. 00:00:13.230 -- 00:00:16.995 After the speaker's presentation, there will be a question and answer session. 00:00:16.995 -- 00:00:22.623 To ask a question during the session, you will need to press star 1-1 on your telephone. 00:00:22.623 -- 00:00:26.548 You will then hear an automated message advising that your hand is raised. 00:00:26.548 -- 00:00:30.980 To withdraw your question, please press star 1-1 again. 00:00:30.980 -- 00:00:34.724 Please be advised that today's conference is being recorded. 00:00:34.724 -- 00:00:38.848 I would now like to hand the conference over to your first speaker today, Lisa Capparelli, 00:00:38.848 -- 00:00:43.032 Vice President of Investor Relations. Please go ahead. 00:00:43.032 -- 00:00:47.837 Thank you, Jill. Good morning, everyone, and thank you for joining Arbutus' second quarter 00:00:47.837 -- 00:00:51.841 2024 financial results and corporate update call. 00:00:51.841 -- 00:00:57.307 Joining me today from the Arbutus executive team are Mike McElhall, Interim President 00:00:57.307 -- 00:01:03.030 and Chief Executive Officer, Dr. Karen Sims, Chief Medical Officer, Dave 00:01:03.030 -- 00:01:06.155 Hastings, Chief Financial Officer, and Dr. 00:01:06.155 -- 00:01:11.402 Mike Sophia, Chief Scientific Officer. Mike McElhall will begin with a corporate 00:01:11.402 -- 00:01:16.889 update, followed by Karen, who will review our ongoing clinical programs. 00:01:16.889 -- 00:01:22.718 Dave will then provide a review of the company's second quarter 2024 fin...